78 related articles for article (PubMed ID: 30686355)
1. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
[TBL] [Abstract][Full Text] [Related]
2. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
Bachy E; Seymour JF; Feugier P; Offner F; López-Guillermo A; Belada D; Xerri L; Catalano JV; Brice P; Lemonnier F; Martin A; Casasnovas O; Pedersen LM; Dorvaux V; Simpson D; Leppa S; Gabarre J; da Silva MG; Glaisner S; Ysebaert L; Vekhoff A; Intragumtornchai T; Le Gouill S; Lister A; Estell JA; Milone G; Sonet A; Farhi J; Zeuner H; Tilly H; Salles G
J Clin Oncol; 2019 Nov; 37(31):2815-2824. PubMed ID: 31339826
[TBL] [Abstract][Full Text] [Related]
3. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.
Locke FL; Rossi JM; Neelapu SS; Jacobson CA; Miklos DB; Ghobadi A; Oluwole OO; Reagan PM; Lekakis LJ; Lin Y; Sherman M; Better M; Go WY; Wiezorek JS; Xue A; Bot A
Blood Adv; 2020 Oct; 4(19):4898-4911. PubMed ID: 33035333
[TBL] [Abstract][Full Text] [Related]
4. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
Bachy E; Le Gouill S; Di Blasi R; Sesques P; Manson G; Cartron G; Beauvais D; Roulin L; Gros FX; Rubio MT; Bories P; Bay JO; Llorente CC; Choquet S; Casasnovas RO; Mohty M; Guidez S; Joris M; Loschi M; Carras S; Abraham J; Chauchet A; Drieu La Rochelle L; Deau-Fischer B; Hermine O; Gastinne T; Tudesq JJ; Gat E; Broussais F; Thieblemont C; Houot R; Morschhauser F
Nat Med; 2022 Oct; 28(10):2145-2154. PubMed ID: 36138152
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Oluwole OO; Bouabdallah K; Muñoz J; De Guibert S; Vose JM; Bartlett NL; Lin Y; Deol A; McSweeney PA; Goy AH; Kersten MJ; Jacobson CA; Farooq U; Minnema MC; Thieblemont C; Timmerman JM; Stiff P; Avivi I; Tzachanis D; Kim JJ; Bashir Z; McLeroy J; Zheng Y; Rossi JM; Johnson L; Goyal L; van Meerten T
Br J Haematol; 2021 Aug; 194(4):690-700. PubMed ID: 34296427
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
[TBL] [Abstract][Full Text] [Related]
7. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
[TBL] [Abstract][Full Text] [Related]
8. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
Maus MV; Alexander S; Bishop MR; Brudno JN; Callahan C; Davila ML; Diamonte C; Dietrich J; Fitzgerald JC; Frigault MJ; Fry TJ; Holter-Chakrabarty JL; Komanduri KV; Lee DW; Locke FL; Maude SL; McCarthy PL; Mead E; Neelapu SS; Neilan TG; Santomasso BD; Shpall EJ; Teachey DT; Turtle CJ; Whitehead T; Grupp SA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335028
[TBL] [Abstract][Full Text] [Related]
9. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
10. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Campo E; Jaffe ES; Cook JR; Quintanilla-Martinez L; Swerdlow SH; Anderson KC; Brousset P; Cerroni L; de Leval L; Dirnhofer S; Dogan A; Feldman AL; Fend F; Friedberg JW; Gaulard P; Ghia P; Horwitz SM; King RL; Salles G; San-Miguel J; Seymour JF; Treon SP; Vose JM; Zucca E; Advani R; Ansell S; Au WY; Barrionuevo C; Bergsagel L; Chan WC; Cohen JI; d'Amore F; Davies A; Falini B; Ghobrial IM; Goodlad JR; Gribben JG; Hsi ED; Kahl BS; Kim WS; Kumar S; LaCasce AS; Laurent C; Lenz G; Leonard JP; Link MP; Lopez-Guillermo A; Mateos MV; Macintyre E; Melnick AM; Morschhauser F; Nakamura S; Narbaitz M; Pavlovsky A; Pileri SA; Piris M; Pro B; Rajkumar V; Rosen ST; Sander B; Sehn L; Shipp MA; Smith SM; Staudt LM; Thieblemont C; Tousseyn T; Wilson WH; Yoshino T; Zinzani PL; Dreyling M; Scott DW; Winter JN; Zelenetz AD
Blood; 2022 Sep; 140(11):1229-1253. PubMed ID: 35653592
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Gauthier J
Bull Cancer; 2018 Dec; 105 Suppl 2():S214-S217. PubMed ID: 30686360
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Le Bourgeois A
Bull Cancer; 2018 Dec; 105 Suppl 2():S188-S197. PubMed ID: 30686357
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Chabannon C; Larghero J
Bull Cancer; 2018 Dec; 105 Suppl 2():S198-S204. PubMed ID: 30686358
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Salles G; Sesques P; Ferrant E; Safar V; Ghesquieres H; Bachy E
Bull Cancer; 2018 Dec; 105 Suppl 2():S168-S177. PubMed ID: 30686355
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Dourthe MÉ; Yakouben K; Chaillou D; Lesprit E; Dalle JH; Baruchel A
Bull Cancer; 2018 Dec; 105 Suppl 2():S147-S157. PubMed ID: 30686353
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Rahal I; Cabannes-Hamy A; Boissel N
Bull Cancer; 2018 Dec; 105 Suppl 2():S158-S167. PubMed ID: 30686354
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
